Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

G1 Therapeutics Inc (NQ: GTHX )

3.910 -0.040 (-1.01%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 492,235
Open 4.010
Bid (Size) 3.910 (4)
Ask (Size) 3.960 (5)
Prev. Close 3.950
Today's Range 3.842 - 4.060
52wk Range 1.080 - 6.140
Shares Outstanding 42,705,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
While there’s no denying that G1 Therapeutics stock is highly speculative, investors should still check under the hood. 
Via InvestorPlace

Performance

YTD
+25.72%
+25.72%
1 Month
+77.73%
+77.73%
3 Month
+1.30%
+1.30%
6 Month
+1.82%
+1.82%
1 Year
+64.29%
+64.29%

More News

Read More
Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble
Via InvestorPlace
Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears
Via InvestorPlace
Exposures Product Safety
Analyst Ratings For G1 Therapeutics
Via Benzinga
Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
Via Benzinga
Breaking Down G1 Therapeutics: 5 Analysts Share Their Views
Via Benzinga
Ginkgo Bioworks Layoffs 2024: What to Know About the Latest DNA Job Cuts
Via InvestorPlace
Topics Workforce
Exposures Layoff
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares Surge
Via Benzinga
Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday?
Via Benzinga
Why Is G1 Therapeutics (GTHX) Stock Down 56% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
From G1 Therapeutics
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
From G1 Therapeutics
Via GlobeNewswire
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
From G1 Therapeutics
Via GlobeNewswire
What's Going On With G1 Therapeutics Stock?
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
GTHX Stock Earnings: G1 Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
From G1 Therapeutics
Via GlobeNewswire
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
From G1 Therapeutics
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.